Safety of Anti-Tumor Necrosis Factor Therapies in Arthritis Patients by Radu M Nanau, Manuela G Neuman

“…Yet biotechnology and pharmaceutical companies conducting research and providing therapeutics in this area frequently face challenges in patient safety.  …”
Get full text

A review of the most common patient-reported outcomes in COPD – revisiting current knowledge and estimating future challenges by Cazzola M, Hanania NA, MacNee W, Rüdell K, Hackford C, Tamimi N

“…This suggests a great need for more information about the patient experience of treatment benefit, but this also may pose challenges to researchers, clinicians, and other important stakeholders (eg, regulatory agencies, pharmaceutical companies) who develop new treatment entities and payers (including but not limited to health technology assessment agencies such as the National Institute for Health and Care Excellence and the Canadian Agency for Drugs and Technologies in Health). …”
Get full text

The value of co-creating a clinical outcome assessment strategy for clinical trial research: process and lessons learnt by Thomas Morel, Karlin Schroeder, Sophie Cleanthous, John Andrejack, Geraldine Blavat, William Brooks, Lesley Gosden, Carroll Siu, Natasha Ratcliffe, Ashley F. Slagle

“…Conclusions Conducting PRO research, in the context of clinical development involving pharmaceutical companies, requires balancing regulatory and scientific rigor with tight time constraints. …”
Get full text

Intention to participate in COVID-19 vaccine clinical trials in May 2021: a cross-sectional survey in the general French population by Amandine Gagneux-Brunon, Jeremy K. Ward, Marion Bonneton, Pierre Verger, Odile Launay, Elisabeth Botelho-Nevers

“…Factors independently negatively associated with willingness to participate in a COVID-19 VCT were female gender with an adjusted odd ratio (aOR) 0.42 and 95% confidence interval (95% CI) 0.35–0.51, and mistrust in health actors (in their own physician and pharmacists, health ministry, government, scientists in medias, medias and pharmaceutical companies) with aOR 0.86 (95% CI 0.84–0.88) by one-point increase in mistrust in health actors score. …”
Get full text

Why (not) go east? Comparison of findings from FDA Investigational New Drug study site inspections performed in Central and Eastern Europe with results from the USA, Western Europe... by Caldron PH, Gavrilova SI, Kropf S

“…Paul H Caldron1, Svetlana I Gavrilova2, Siegfried Kropf31Midwestern University, Arizona College of Osteopathic Medicine, Glendale, AZ, USA; 2Mental Health Research Center of the Russian Academy of Medical Sciences, Moscow, Russian Federation; 3Institute for Biometrics und Medical Informatics, Otto von Guericke University of Magdeburg, Magdeburg, GermanyAbstract: Since the mid-1990s, investigational sites in the countries of Central and Eastern Europe (CEE) have been increasingly utilized by pharmaceutical companies because of their high productivity in terms of patient enrolment into clinical trials. …”
Get full text

“Our fear is finished,” but nothing changes: efforts of marginalized women to foment state accountability for maternal health care in a context of low state capacity by Marta Schaaf, Jashodhara Dasgupta

“…Several features of the micro and macro context shaped the trajectory of SAHAYOG’s efforts, including deeply rooted caste dynamics, low provider commitment to ending informal payments, the embeddedness of informal payments, human resources scarcity, and the overlapping private interests of pharmaceutical companies and providers. Conclusion Though changes were manifest in certain fora, providers have not necessarily embraced the notion of low caste, tribal, or Muslim women as citizens with entitlements, especially in the context of free government services for childbirth. …”
Get full text

Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China by Zhonghan Zhang, Fan Luo, Jiaxin Cao, Feiteng Lu, Yang Zhang, Yuxiang Ma, Kangmei Zeng, Li Zhang, Hongyun Zhao

“…Clinical trials were divided into two categories based on the attributes of pharmaceutical companies (international or China-initiated or involved). …”
Get full text

In silico prediction of novel therapeutic targets using gene–disease association data by Enrico Ferrero, Ian Dunham, Philippe Sanseau

“…Here, we explore whether gene–disease association data from the Open Targets platform is sufficient to predict therapeutic targets that are actively being pursued by pharmaceutical companies or are already on the market. Methods To test our hypothesis, we train four different classifiers (a random forest, a support vector machine, a neural network and a gradient boosting machine) on partially labelled data and evaluate their performance using nested cross-validation and testing on an independent set. …”
Get full text

IMPAACT: IMproving the PArticipAtion of older people in policy decision-making on common health CondiTions – a study protocol by Simon Stewart, Michael Lawless, Renuka Visvanathan, Danielle Taylor, Mandy Archibald, Hannah M O'Rourke, Matthew J Leach, Mark Thompson, Justin Beilby, Rachel C Ambagtsheer, Kathy Williams, Annette Braunack-Mayer, Victoria Cornell, Catherine J Hurley, Elsa Dent, Lyn Whiteway, Agnieszka Chudecka

“…Second, representatives from a range of key stakeholder groups, including consumers and carers, health and aged care policymakers, general practitioners, practice nurses, geriatricians, allied health practitioners, pharmaceutical companies, private health insurers and community and aged care providers (n=40) will be purposively recruited for two Policy Roundtables. …”
Get full text

Final ORBIS project conference by Marcin Skotnicki, Janina Lulek

“…Poznan University of Medical Sciences coordinated this international and cross‑sectoral project with fourteen academic institutions and pharmaceutical companies from eight countries. The goal of ORBIS was research and training cooperation between universities and the industry sector to develop better, more effective, modern drugs. …”
Get full text

Funders' data-sharing policies in therapeutic research: A survey of commercial and non-commercial funders. by Jeanne Fabiola Gaba, Maximilian Siebert, Alain Dupuy, David Moher, Florian Naudet

“…All 78 eligible non-commercial funders retrieved from the Sherpa/Juliet Initiative website and a random sample of 100 commercial funders selected from pharmaceutical association member lists (LEEM, IFPMA, EFPIA) and the top 100 pharmaceutical companies in terms of drug sales were included. …”
Get full text

تقويم فرص تطبيق إعادة هندسة العمليات كمدخل لتحسين القدرة التنافسية دراسة ميدانية على شركات صناعة الدواء الحاصلة على شهادة الأيزو في محافظة حلب... by صلاح شيخ ديب

“…This study investigates the evaluation of opportunities of an application business process reengineering as an approach for improving  competitiveness in pharmaceutical companies in Aleppo. This approach depends on the basic rethinking and redesign operations for achieving a direct improvement in the normal performance measurements. …”
Get full text

始发表现为轻型卒中的急性大血管闭塞的血管内治疗中国专家共识2023 Chinese Expert Consensus 2023 on Endovascular Treatment for Acute Large Vessel Occlusion with Mild Stroke... by 中国卒中学会神经介入分会

“…The aim is to provide guidance for professionals and social workers engaged in stroke prevention and treatment, especially the endovascular treatment, care and rehabilitation of acute ischemic stroke, as well as relevant governmental agencies, healthcare administrators, pharmaceutical companies, healthcare demand parties, and other stakeholders. …”
Get full text

Barriers to rational antibiotic prescription in Iran: a descriptive qualitative study by Ramin Sami, Kobra Salehi, Raheleh Sadegh, Hamid Solgi, Vajihe Atashi

“…The subcategories of these categories were physicians’ limited professional knowledge, physicians’ poor attitude towards RAP, physicians’ routine-based practice instead of evidence-based practice, physicians’ limited accountability, physicians’ fear over the legal consequences of not prescribing antibiotics, physicians’ financial motives, limited access to quality educational materials, poor in-service training for physicians, lack of culturally appropriate guidelines, inefficiency of the stewardship committee, limited supervision of physicians’ performance, ineffective managerial supervision, limited supervision of sampling for antimicrobial susceptibility testing, sociocultural factors contributing to irrational antibiotic prescription, poor adherence of insurance companies to their financial commitments, and financial incentives of pharmaceutical companies for physicians. Conclusion The barriers to RAP are different and complex and include physician-related, resource-related, supervision-related, and contextual factors. …”
Get full text

Validation of technological process of preparation hymoding cream with hyaluronic acid by T. G. Yarnykh, G. M. Melnik, O. A. Rukhmakova

“…To date, in the mass production of medicines both in pharmaceutical companies and in pharmacies, more and more attention is paid to the practice of process validation. …”
Get full text

Cost-effectiveness analysis of tocilizumab in combination with methotrexate for rheumatoid arthritis: A Markov model based on data from Serbia, country in socioeconomic transition by Kostić Marina, Jovanović Snežana, Tomović Marina, Popović-Milenković Marija, Janković Slobodan M.

“…In order to start using expensive biologic medicines in patients in transitional countries, special strategy and pricing policy of international pharmaceutical companies are necessary, which would include calculation of prices of biologic medicines on the basis of local pharmacoeconomic studies. …”
Get full text

Therapeutic drug monitoring to personalize dosing of imatinib, sunitinib, and pazopanib: A mixed methods study on barriers and facilitators by Kim Westerdijk, Neeltje Steeghs, Casper S. J. Tacke, Winette T. A. van derGraaf, Nielka P. vanErp, Gerard vanOortmerssen, Rosella P. M. G. Hermens, Ingrid M. E. Desar, In collaboration with the Dutch Pharmacology Oncology Group (DPOG)

“…Methods We performed a mixed methods study among all stakeholders involved: patients, healthcare professionals (HCPs), pharmaceutical companies, and health insurance companies. During the first qualitative part of this study, we performed semi‐structured individual interviews and one focus group interview to identify all (potential) barriers and facilitators, and during the second quantitative part of this study, we used a web‐based survey to quantify these findings. …”
Get full text

Public-private partnership (3Ps) in ensuring safe use of medicines: An Indian experience by Vivekanandan Kalaiselvan, Shatrunajay Shukla, Shubhang Arora, Tarani Prakash Shrivastava, Rajeev Singh Raghuvanshi

“…Under PvPI, Central or State Government medical institutions/hospitals and public health programmes constitute public partners while private medical institutions/hospitals, pharmaceutical companies, corporate hospitals and professional bodies account for private partners. …”
Get full text

Potential Impact of Subsequent Entry Biologics in Nephrology Practice in Canada by Daniel J Martinusen, Clifford Lo, Judith G Marin, Nicole W Tsao, Marianna Leung

“…Sources of information: Sources of information include published literature and reports available in the public domain including guidelines obtained from regulatory agencies and information shared by Pharmaceutical companies. Lastly, we generated information from our own focus group consisting of nephrologists, a regulatory body representative, a hospital formulary representative, a patient representative, a hospital administrator, and a health economist. …”
Get full text

<i>Tamarindus indica</i> Extract as a Promising Antimicrobial and Antivirulence Therapy by Mohamed F. Ghaly, Marzough Aziz Albalawi, Mahmoud M. Bendary, Ahmed Shahin, Mohamed A. Shaheen, Abeer F. Abu Eleneen, Mohammed M. Ghoneim, Ayman Abo Elmaaty, Mohamed F. M. Elrefai, Sawsan A. Zaitone, Amira I. Abousaty

“…In conclusion, we hope that pharmaceutical companies can utilize our findings to produce a new formulation of <i>T. indica</i> ethanolic extract with other antibiotics.…”
Get full text